CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING, L. DE PAOLI, J. DELGADO, K. G. RABE, M. GENTILE, Michael DOUBEK, F. R. MAURO, G. CHIODIN, M. MATTSSON, J. BAHLO, G. CUTRONA, Jana KOTAŠKOVÁ, C. DEAMBROGI, K. E. SMEDBY, V. SPINA, A. BRUSCAGGIN, W. WU, R. MOIA, E. BIANCHI, B. GERBER, E. ZUCCA, S. GILLESSEN, M. GHIELMINI, F. CAVALLI, G. STUSSI, M. A. HESS, T. S. BAUMANN, A. NERI, M. FERRARINI, R. ROSENQUIST, F. FORCONI, R. FOA, Šárka POSPÍŠILOVÁ, F. MORABITO, S. STILGENBAUER, H. DOHNER, S. A. PARIKH, W. G. WIERDA, E. MONTSERRAT, G. GAIDANO, M. HALLEK and D. ROSSI. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. Washington DC, USA: American Society of Hematology, 2020, vol. 135, No 21, p. 1859-1869. ISSN 0006-4971. Available from: https://dx.doi.org/10.1182/blood.2019003453.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
Authors CONDOLUCI, A., L. T. DI BERGAMO, P. LANGERBEINS, M. A. HOECHSTETTER, C. D. HERLING, L. DE PAOLI, J. DELGADO, K. G. RABE, M. GENTILE, Michael DOUBEK (203 Czech Republic, belonging to the institution), F. R. MAURO, G. CHIODIN, M. MATTSSON, J. BAHLO, G. CUTRONA, Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution), C. DEAMBROGI, K. E. SMEDBY, V. SPINA, A. BRUSCAGGIN, W. WU, R. MOIA, E. BIANCHI, B. GERBER, E. ZUCCA, S. GILLESSEN, M. GHIELMINI, F. CAVALLI, G. STUSSI, M. A. HESS, T. S. BAUMANN, A. NERI, M. FERRARINI, R. ROSENQUIST, F. FORCONI, R. FOA, Šárka POSPÍŠILOVÁ (203 Czech Republic, belonging to the institution), F. MORABITO, S. STILGENBAUER, H. DOHNER, S. A. PARIKH, W. G. WIERDA, E. MONTSERRAT, G. GAIDANO, M. HALLEK and D. ROSSI (guarantor).
Edition Blood, Washington DC, USA, American Society of Hematology, 2020, 0006-4971.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 22.113
RIV identification code RIV/00216224:14110/20:00117894
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1182/blood.2019003453
UT WoS 000535968000010
Keywords in English chronic lymphocytic leukemia; prognostic score
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 19/1/2021 14:21.
Abstract
Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage disease and managed with active surveillance. The individual course of patients with early-stage CLL is heterogeneous, and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in patients with CLL with early, asymptomatic disease (International Prognostic Score for Early-stage CLL [IPS-E]). Individual patient data from 11 international cohorts of patients with early-stage CLL (n = 4933) were analyzed to build and validate the prognostic score. Three covariates were consistently and independently correlated with TTFT: unmutated immunoglobulin heavy variable gene (IGHV), absolute lymphocyte count higher than 15 x 10(9)/L, and presence of palpable lymph nodes. The IPS-E was the sum of the covariates (1 point each), and separated low-risk (score 0), intermediate-risk (score 1), and high-risk (score 2-3) patients showing a distinct TTFT. The score accuracy was validated in 9 cohorts staged by the Binet system and 1 cohort staged by the Rai system. The C-index was 0.74 in the training series and 0.70 in the aggregate of validation series. By meta-analysis of the training and validation cohorts, the 5-year cumulative risk for treatment start was 8.4%, 28.4%, and 61.2% among low-risk, intermediate-risk, and high-risk patients, respectively. The IPS-E is a simple and robust prognostic model that predicts the likelihood of treatment requirement in patients with early-stage CLL. The IPS-E can be useful in clinical management and in the design of early intervention clinical trials.
Links
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
NV19-03-00091, research and development projectName: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby
Investor: Ministry of Health of the CR
PrintDisplayed: 10/7/2024 05:00